Inflammatory and Immunological parameters in adults with Down syndrome

Immunity and Ageing

Volumn 8, Issue , 2011, Pages

  Trotta, Maria B F ^a   Serro Azul, João B ^a   Wajngarten, Mauricio ^a   Fonseca, Simone G ^a   Goldberg, Anna C ^b   Kalil, Jorge E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADULT DISEASE; AGING; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; INFLAMMATION; INTELLECTUAL IMPAIRMENT; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR OF CALCINEURIN 1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79955101574     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-8-4     Document Type: Article

References (54)

1. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002, 359:1019-25. 10.1016/S0140-6736(02)08092-3, 11937181.
2. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-69. 10.1016/S0140-6736(99)05264-2, 10675114.
3. Licastro F, Marocchi A, Penco S, Porcellini E, Lio D, Dogliotti G, Corsi MM. Does Down's syndrome support the homocysteine theory of atherogenesis?. Arch Gerontol Geriatr 2006, 43(3):381-7. 10.1016/j.archger.2006.01.003, 16533539.
4. Ylä-Herttuala S, Luoma J, Nikkari T, Kivimäki T. Down's syndrome and atherosclerosis. Atherosclerosis 1989, 76(2-3):269-72. 10.1016/0021-9150(89)90110-X, 2525042.
5. Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down's syndrome: an atheroma free-model?. British Medical Journal 1977, 2:226-228. 10.1136/bmj.2.6081.226, 1631400, 141966.
6. Dogliotti G, Galliera E, Licastro F, Corsi MM. Age-related changes in plasma levels of BDNF in Down syndrome patients. Immunity & Ageing 2010, 7:2. 10.1186/1742-4933-7-2, 21567389.
7. Cuadrado E, Barrena MJ. Immune dysfunction in Down syndrome: primary immune deficiency or early senescence of the immune system?. Clin Immunol Immunopathol 1996, 78:209-14. 10.1006/clin.1996.0031, 8605695.
8. Yasui K, Shinozaki K, Nakazawa T, Agematsu K, Komiyama A. Presenility of granulocytes in Down syndrome individuals. Am J Med Genet 1999, 84:406-12. 10.1002/(SICI)1096-8628(19990611)84:5<406::AID-AJMG4>3.0.CO;2-4, 10360394.
9. Corsi MM, Ponti W, Venditti A, Ferrara F, Baldo C, Chiappelli M, Licastro F. Proapoptotic activated T-cells in the blood of children with Down's syndrome: relationship with dietary antigens and intestinal alterations. Int J Tissue React 2003, 25(3):117-25.
10. Li Volti S, Mattina T, Mauro L, Bianca S, Anfuso S, Ursino A, Mollica F. Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome. Child Nerv Syst 1996, 12:100-2.
11. McKay E, Hems G, Massie A, Moffat MA, Phillips KM. Serum antibody to poliovirus in patients in a mental deficiency hospital, with particular reference to Down's syndrome. J Hyg (Lond) 1978, 81:25-30. 10.1017/S0022172400053730, 2129762, 211162.
12. Epstein LB, Philip R. Abnormalities of the immune response to influenza antigen in Down syndrome (trisomy 21). Prog Clin Biol Res 1987, 246:163-82.
13. Philip R, Berger AC, McManus NH, Warner NH, Peacock MA, Epstein LB. Abnormalities of the in vitro cellular and humoral responses to tetanus and influenza antigens with concomitant numerical alterations in lymphocyte subsets in Down syndrome (trisomy 21). J Immunol 1986, 136:1661-7.
14. Costa-Carvalho BT, Martinez RM, Dias AT, Kubo CA, Barros-Nunes P, Leiva L, Solé D, Carneiro-Sampaio MM, Naspitz CK, Sorensen RU. Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients. Braz J Med Biol Res 2006, 39:1587-92. 10.1590/S0100-879X2006005000047, 17160268.
15. Ferreira CT, Leite JC, Taniguchi A, Vieira SM, Pereira-Lima J, da Silveira TR. Immunogenicity and safety of an inactivated hepatitis A vaccine in children with Down syndrome. J Pediatr Gastroenterol Nutr 2004, 39:337-40. 10.1097/00005176-200410000-00007, 15448421.
16. Hawkes RA, Boughton CR, Schroeter DR. The antibody response of institutionalized Down's syndrome patients to seven microbial antigens. Clin Exp Immunol 1978, 31:298-304. 1541221, 148342.
17. Troisi CL, Heiberg DA, Hollinger FB. Normal immune response to hepatitis B vaccine in patients with Down's syndrome. A basis for immunization guidelines. JAMA 1985, 254:3196-9. 10.1001/jama.254.22.3196, 2933533.
18. do Canto CL, Granato CF, Garcez E, Villas Boas LS, Fink MC, Estevam MP, Pannuti CS. Cytomegalovirus infection in children with Down syndrome in a day-care center in Brazil. Rev Inst Med Trop Sao Paulo 2000, 42:179-83. 10.1590/S0036-46652000000400001, 10968879.
19. Murphy M, Insoft RM, Pike-Nobile L, Epstein LB. A hypothesis to explain the immune defects in Down syndrome. Prog Clin Biol Res 1995, 393:147-67.
20. Roberts-Thomson IC, Whittingham S, Youngchaiyud U, MacKay IR. Ageing, immune response and mortality. Lancet 1974, 2:368. 10.1016/S0140-6736(74)91755-3, 4136513.
21. Martin GM. Genetic modulation of senescent phenotypes in Homo sapiens. Cell 2005, 120(4):523-32. 10.1016/j.cell.2005.01.031, 15734684.
22. Fuentes JJ, Genesca L, Kingsbury TJ, Cunningham KW, Perez-Riba M, Stivill X, la Luna S. DSCR1 overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Human Molecular Genetics 2000, 11(9):1681-90.
23. Harris CD, Ermak G, Davies KJ. DSCR1 (Adapt78 or RCAN1) in disease. Cell Mol Life Sci 2005, 62:2477-2486. 10.1007/s00018-005-5085-4, 16231093.
24. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992, 89:3686-90. 10.1073/pnas.89.9.3686, 525555, 1373887.
25. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duddy R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 2000, 87:E61-68.
26. Burgio GR, Ugazio AG, Nespoli L, Marcioni AF, Bottelli AM, Pasquali F. Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages. Eur J Immunol 1975, 5:600-3. 10.1002/eji.1830050904, 11993318.
27. Seger R, Buchinger G, Ströder J. On the influence of age on immunity in Down's syndrome. Eur J Pediatr 1977, 124:77-87. 10.1007/BF00477543, 137810.
28. Cossarizza A, Monti D, Montagnani G, Ortolani C, Masi M, Zannotti M, Franceschi C. Precocious aging of the immune system in Down syndrome: alterations of B lymphocytes, T-lymphocyte subsets, and cells with natural killer markers. Am J Med Genet Suppl 1990, 7:213-8.
29. Licastro F, Mariani RA, Faldella G, Carpenè E, Guidicini G, Rangoni A, Grilli T, Bazzocchi G. Immune-endocrine status and coeliac disease in children with Down's syndrome: relationships with zinc and cognitive efficiency. Brain Res Bull 2001, 55(2):313-7. 10.1016/S0361-9230(01)00476-2, 11470333.
30. Franceschi C, Bonafè M. Centenarians as a model for healthy aging. Biochem Soc Trans 2003, 31:457-61. 10.1042/BST0310457, 12653662.
31. Ewart JL, Auerbach R. Defects in thymocyte differentiation and thymocyte-stromal interactions in the trisomy 16 mouse. Dev Immunol 1992, 2:215-26. 10.1155/1992/72627, 2275860, 1378332.
32. Murphy M, Friend DS, Pike-Nobile L, Epstein LB. Tumor necrosis factor alpha and IFN-gamma expression in human thymus. J Immunol 1992, 149:2506-12.
33. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, Marcato A, Passeri G, Ortolani C, Forti E, Fagiolo U, Passeri M, Franceschi C. Lymphocyte Subsets and Natural Killer Cell Activity in Healthy Old People and Centenarians. Blood 1993, 82:2767-73.
34. Elsayed SM, Elsayed GM. Phenotype of apoptotic lymphocytes in children with Down syndrome. Immunity & Ageing 2009, 6:2. 10.1186/1742-4933-6-2, 21567389.
35. Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol 2008, 59(Suppl 9):169-86.
36. Ugazio AG, Maccario R, Notarangelo LD, Burgio GR. Immunology of Down syndrome: A review. Am J Med Genet 1990, 204-12.
37. Vaziri H, Schächter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley CB. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993, 52:661-7. 1682068, 8460632.
38. Murphy M, Lempert MJ, Epstein LB. Decreased level of T cell receptor expression by Down syndrome (trisomy 21) thymocytes. Am J Med Genet 1990, 7:234-7.
39. Franciotta D, Verri A, Zardini E, Andreoni L, De Amici M, Moratti R, Nespoli L. Interferon-gamma- and interleukin-4-producing T cells in Down's syndrome. Neurosci Lett 2006, 395:67-70. 10.1016/j.neulet.2005.10.048, 16289322.
40. Lio D, Candore G, Crivello A, Scola L, Colonna-Romano, Cavallone L, Hoffmann E, Caruso M, Licastro F, Caldarera CM, Branzi A, Francheschi C, Caruso C. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases ans in sucessful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet 2004, 41:790-94. 10.1136/jmg.2004.019885, 1735604, 15466015.
41. Licastro F, Chiappelli M, Porcellini E, Trabucchi M, Marocchi A, Corsi MM. Altered vessel signalling molecules in subjects with Down's syndrome. Int J Immunopathol Pharmacol 2006, 19(1):181-5.
42. Licastro F, Chiappelli M, Ruscica M, Carmelli V, Corsi MM. Altered cytokine and acute phase response protein levels in the blood of children with Down syndrome. Int J Immunopathol Pharmacol 2005, 18:165-172.
43. Fuentes JJ, Pritchard MA, Estivill X. Genomic organization, alternative splicing and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics 1997, 44:358-361. 10.1006/geno.1997.4866, 9325060.
44. Ermak G, Morgan TE, Davies KJ. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J Biol Chem 2001, 276:38787-94. 10.1074/jbc.M102829200, 11483593.
45. Lizuka M, Abe M, Shiiba K, Sasaki I, Sato Y. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J Vasc Res 2004, 4:334-44.
46. Kim YS, Cho KO, Lee HJ, Kim SY, Sato Y, Cho YJ. Down Syndrome Candidate Region 1 Increases the Stability of the IκBα Protein. IMPLICATIONS FOR ITS ANTI-INFLAMMATORY EFFECTS. The Journal of Biological Chemistry 2006, 281:39051-61. 10.1074/jbc.M604659200, 17062574.
47. Saran NG, Pletcher MT, Natale JE, Cheng Y, Reeves RH. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet 2003, 12:2013-19. 10.1093/hmg/ddg217, 12913072.
48. Shapiro BL. Developmental instability of the cerebellum and its elevance to Down syndrome. J Neural Transm 2001, 61(Suppl):11-34.
49. Patterson D. Molecular genetic analysis of Down syndrome. Hum Genet 2009, 126:195-214. 10.1007/s00439-009-0696-8, 19526251.
50. Aït Yahya-Graison E, Aubert J, Dauphinot L, Rivals I, Prieur M, Golfier G, Rossier J, Personnaz L, Creau N, Bléhaut H, Robin S, Delabar JM, Potier MC. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 2007, 81:475-91. 10.1086/520000, 1950826, 17701894.
51. Boyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 1974, 4:269-74. 10.1111/j.1399-0039.1974.tb00252.x, 4415728.
52. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
53. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30:e36. 10.1093/nar/30.9.e36, 113859, 11972351.
54. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods 2001, 25:402-8. 10.1006/meth.2001.1262, 11846609.